Seagen has been granted a patent for methods of producing T cells with reduced fucosylation for use in cancer treatment. The method involves culturing T cells with a fucose analog in a cell culture medium. GlobalData’s report on Seagen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Seagen, Nanoparticle drug conjugates was a key innovation area identified from patents. Seagen's grant share as of February 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Reduced fucosylation in t cells for cancer treatment
A recently granted patent (Publication Number: US11891644B2) discloses a method for producing T cells with reduced surface fucosylation. The method involves culturing T cells in the presence of a fucose analog in a cell culture medium. Additionally, the process includes isolating the T cells with reduced surface fucosylation, with specific fucose analogs such as 2-deoxy-2-fluoro-L-fucose and alkynyl fucose peracetate being utilized in the method.
Furthermore, the patent claims specify that the T cells targeted for reduced surface fucosylation are human peripheral T cells, with a significant reduction of at least 85%, 90%, or 95% relative to T cells cultured without the fucose analog. This innovative method offers a promising approach for manipulating T cell surface characteristics, potentially opening new avenues for therapeutic applications in various medical fields.
To know more about GlobalData’s detailed insights on Seagen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.